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July 14, 2015 rate of diseased cardiomyocytes that are deficient in holocytochrome-c synthase, an enzyme that is essential for mitochondrial respiration. Although this approach and others examined the role of cell competition during cardiac development, 13 they did not directly address the consequences of cardiomyocyte loss. Accordingly, the ability of an embryonic mammalian heart to regenerate after rapid and extensive cell loss has yet to be addressed.
In this study, we used a novel blastocyst complementation strategy to test the ability of a mammalian embryonic heart to compensate for rapid cardiac cell loss and to quantitatively define the extent of cardiac lineage cell ablation that is compatible with normal development. We hypothesized that genetically mediated cell loss in the mouse heart can be fully compensated for by residual nonablated cells if a robust regenerative mechanism exists at the cardiac progenitor cell (CPC) or immature cardiomyocyte stage of development and found that ablation of up to 50% to 60% of CPCs or immature cardiomyocytes is well tolerated and supports live birth to adulthood. Furthermore, we found that proliferation of residual cardiomyocytes is involved in the cell replacement process. Our findings encourage further investigation of the endogenous mechanisms responsible for replacing lost CPCs and cardiomyocytes in the embryonic heart. In the context of adult mammalian cardiac injury, advances in this area may lead to therapies that direct the postinjury response toward cellular regeneration rather than fibrosis.
Methods
An expanded Methods section is available in the online-only Data Supplement.
Experimental Animals
An Nkx2. 5 Cre/+ knock-in mouse line was kindly provided by Dr Robert Schwartz. 14 An αMHC Cre/+ transgenic mouse line was kindly provided by Dr E. Dale Abel.
15 ROSA26 eGFP-DTA and ROSA26 LacZ mouse lines were purchased from The Jackson Laboratory. 16, 17 Experimental animal protocols were approved by the Institutional Animal Care and Use committees of Massachusetts General Hospital and Stanford University. All experiments were performed on somite-matched embryos or sex-matched adult mice.
Establishment of Embryonic Stem Cell Lines
Derivation of the V6.5 18 and R1 19 embryonic stem cell (ESC) lines has been described previously. For generation of Nkx2. 5 Cre/+ ;ROSA26 Cre/+ mice with female ROSA26 eGFP-DTA mice. At 3.5 days postcoitum, females were euthanized and blastocysts were flushed from the uterine horns with M2 medium (M7167, Sigma-Aldrich) and washed several times. With the use of a mouth pipette with a pulled glass capillary, blastocysts were plated individually onto 24-well gelatin-coated plates containing mitomycin-C (M4287, Sigma-Aldrich) inactivated mouse embryonic fibroblast feeder layers in ESC derivation media and cultured, undisturbed, at 37°C in 5% CO 2 in humidified air for 5 to 7 days without media changes. As blastocysts hatched from their zona pellucidae, the inner cell mass outgrowth was identified and transferred into 200 µL of 0.25% trypsin-EDTA solution (25200, Life Technologies) for 5 minutes at 37°C and gently dissociated by pipetting. Trypsin was inactivated with FBS (S11550, Atlanta Biologicals), and the inner cell mass cells were centrifuged and reseeded onto fresh mouse embryonic fibroblasts in ESC maintenance media supplemented with 2i. 20, 21 Undifferentiated ESC colonies were then gradually expanded to establish ESC lines. Lines were selected for further use on the basis of undifferentiated morphology, the presence of the Cre transgene and Y chromosome by polymerase chain reaction, and expression of enhanced green fluorescent protein (eGFP). Primer sequences used for genotyping are listed in Table I in the online-only Data Supplement. ESC derivation and maintenance media compositions are reported in the online-only Data Supplement.
Chimera Production
Embryos were staged by vaginal plugging of the mother, with noon on the day of appearance of the plug designated as embryonic day (E) 0.5. For the initial studies, ≈10 to 20 low-passage (P5-P10) Nkx2.5
Cre/+ ;ROSA26 eGFP-DTA or αMHC
Cre/+ ;ROSA26
eGFP-DTA ESCs were microinjected into E3.5 blastocysts from superovulated CD-1 females (Charles River Laboratories). For the reverse complementation studies, P15 through P25 V6.5 or R1 ESCs were microinjected into E3.5 blastocysts from superovulated ROSA26 eGFP-DTA females that had been mated to Nkx2. 5 Cre/+ males. For both approaches, the injected blastocysts were subsequently transferred into the uterus of 2.5 days postcoitum pseudopregnant 6-to 8-week-old CD-1 foster mothers previously mated with vasectomized males. 22 Genotype was identified on the basis of the expression of eGFP and the presence of the Cre transgene by polymerase chain reaction. Chimeric contribution was determined by flow cytometric analysis, as described in the online-only Data Supplement.
Ex Vivo Single-Cell Clonal Analysis
Details of the single-cell culture studies can be found in the onlineonly Data Supplement.
Immunohistochemistry
For cell culture experiments in 96-well plates, cells were fixed for 5 minutes in 4% paraformaldehyde and washed with PBS. E8.5 embryos were fixed for 10 minutes in 4% paraformaldehyde and embedded in optimal cutting temperature compound on dry ice. E9.5 to E10.5 embryos and live-born mouse tissues were fixed overnight in 4% paraformaldehyde and embedded in paraffin. Tissue blocks were cut at 5-µm thickness. Paraffin-embedded sections underwent antigen retrieval in a pressure cooker for 3 minutes in a citrate-based unmasking solution, pH 6.0 (H-3300, Vector Laboratories). Plated cells and tissue sections were blocked and permeabilized with 10% goat serum, 1% BSA, and 0.1% saponin in PBS for 1 hour and then incubated overnight at 4º C with the primary antibody. Primary antibodies used are listed in Table II 
Quantification of Cardiomyocyte Proliferation
For assessment of cardiomyocyte proliferation, embryo tissue sections were prepared as described in the Immunohistochemistry section with antibodies to cardiac troponin T (cTnT), CD31, and phosphorylated histone H3 or Ki-67. To confirm that each DAPI + cell nucleus counted was associated with a cardiomyocyte (if surrounded in 3 dimensions by cTnT stain) or an endocardial cell (if surrounded in 3 dimensions by a CD31 stain), 1-mm z-stack immunofluorescence
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images of each section were acquired on a Zeiss LSM710 confocal microscope at ×20 magnification.
Echocardiography
Echocardiography was performed on 4-to 5-week-old mice with a 13-MHz linear-array transducer with a digital ultrasound system (Vivid 7, GE Medical Systems, Milwaukee, WI). The mice were lightly sedated with an intraperitoneal injection of ketamine (50 mg/kg). Heart rate, left ventricular internal diameter at end diastole, and left ventricular internal diameter at end systole were measured, and the left ventricular fractional shortening was calculated by use of an M-mode echocardiogram obtained at the midpapillary level. For each mouse, all values were averaged from measurements obtained from 9 cardiac cycles. All measurements and calculations were performed by an operator blinded to the mouse genotype. 
Statistical Analysis

Results
Fractional Ablation of Embryonic CPCs by Chimeric Complementation
The myocardial lineage of the heart arises from first and second heart field cells that express Nkx2.5, a key transcription factor in early heart formation ( Figure I in the online-only Data Supplement). 23 We performed targeted genetic ablation of Nkx2.5 + CPCs during embryonic development to examine the innate recovery response by the remaining nonablated cells. By crossing a previously described Nkx2.5-Cre knockin mouse line (Nkx2.5
Cre/+ ) 14 with a mouse line that expressed diphtheria toxin A (DTA) after Cre-dependent excision of a constitutively active eGFP transgene (ROSA26 eGFP-DTA ), 16 we show that cardiac cells were abolished entirely in doubletransgenic embryos ( Figure 1A) .
Although the complete ablation of CPCs demonstrates the essential requirement of these cells in normal embryogenesis, it does not lend itself to a strategy for examining the regenerative potential of the fetal heart. One solution may be to use a drug-inducible cardiac-specific Cre model; however, our previous experience with either doxycycline-or tamoxifeninducible mice suggests too much interembryo variability in drug metabolism in utero for that strategy to be reliable for our purposes. 24 Hence, we used a novel strategy that involves injection of double-transgenic Nkx2.5
eGFP-DTA
ESCs into wild-type eGFP − blastocysts to ablate CPCs in quantifiable fractions ( Figure 1B ). Because ESC injection into mouse blastocysts is well known to generate chimeric embryos and mice with a wide spectrum of ESC contribution, 25 this assay enabled us to determine the expected percentage of CPC ablation by assessing the overall contribution of the eGFP +
Nkx2.5
Cre/+ ;ROSA26 eGFP-DTA ESCs to the embryo. We first generated several independent ESC lines carrying both the Nkx2. 5 Cre/+ and ROSA26 eGFP-DTA alleles ( Figure 1C ). These ES clones were eGFP + under fluorescence microscopy, indicating the presence and expression of the floxed eGFP transgene. Three such clones (Nkx-DTA1, Nkx-DTA2, and Nkx-DTA3) that exhibited normal proliferation rates and an otherwise healthy in vitro phenotype were subsequently injected into wild-type eGFP − blastocysts and fostered in pseudopregnant female mice. After injection of 602 wild-type blastocysts, we obtained 414 embryos and mice with a broad range of eGFP + ESC contribution ( Figure 1D ). Within each chimeric embryo, CPCs derived from injected eGFP + ESCs were expected to die as a result of Cre-mediated expression of DTA so that directly assessing the percentage of cardiac contribution by eGFP + ESCs would not have been possible ( Figure 1E ). To overcome this limitation, we examined the expected variance in ESC contribution to the heart relative to other portions of the embryo body (head, limbs, tail, etc.) by injecting wild-type eGFP − ESCs into eGFP + mouse blastocysts or red fluorescent tdTomato + ESCs into wild-type mouse blastocysts. By flow cytometric (fluorescence-activated cell sorter [FACS] ) analysis, we found that 97% of the embryos (29 of 30) showed a difference of ≤12% in ESC contribution to the heart compared with their mean contribution to the rest of the embryo ( Figure IIA -IID in the online-only Data Supplement). Remarkably, our analysis of the E10.5 chimeric embryos from Nkx2.5
Cre/+
;ROSA26
eGFP-DTA ESC injections showed that the ablation of up to ≈60% of CPCs, as determined by FACS, appears compatible with normal development, whereas degrees of ablation >60% lead to overall developmental arrest ( Figure 1F ).
Immunohistological analysis of chimeric embryos showed that eGFP + cell contribution was homogenously distributed throughout the embryo except for the heart region, where eGFP + cells were completely absent within the cTnT + cell population ( Figure 2A ). Consistent with this, the hearts of chimeric embryos showed an absence of eGFP fluorescence (arrows), supporting the high efficiency of CPC ablation and compensation from adjacent nonablated eGFP − cardiac cells ( Figure 1F ). Of note, sporadic eGFP + cells could be found in the endocardium, consistent with the previously described incomplete expression of Nkx2.5 in these cells 26 ( Figure 2A ). Interestingly, the gross morphology and myocardial cellularity were similar between surviving embryos with up to 60% ablation and their stage-matched littermate controls without ESC chimerism, supporting the presence of a regenerative process to compensate for lost CPCs and their myocardial descendants (Figure 2A ).
To elucidate potential compensatory processes that might account for the recovery of lost CPCs, we performed immunostaining for transcription factors (ie, Gata4, Mef2c, Islet-1) and signaling mediators (ie, β-catenin and Yap) that have been reported to regulate CPC number or myocardial growth [27] [28] [29] ( Figure 2B-2G) . However, these proteins exhibited high baseline expression during this early stage of development in control embryos; thus, no qualitative difference in expression 
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could be observed in the ablated embryo heart by immunofluorescence staining. We also examined whether the expression of sarcomeric proteins (ie, cTnT, α-actinin, myosin light chain 2v) varied between ablated and control hearts and found no difference in these parameters ( Figure 2H-2J ). Together, these data support an efficient compensatory response by residual unablated CPCs or their myocardial descendants to rapidly recover full myocardial cellularity in the ablated heart. , and DAPI staining of embryonic day (E) 8.5 and E10.5 chimeric embryos with up to ≈50% CPC ablation. By E8.5, all eGFP + myocardial cells have been ablated in the heart. Rare, scattered eGFP + endocardial cells can be identified (arrow). Cardiac chamber morphology and cellularity in the compact and trabecular compartments are similar between control and ablated hearts, suggesting a rapid restoration of myocardial cell number after ablation. Note that eGFP + staining in the atria of the E10.5 control embryo represents autofluorescent blood cells. B through J, Immunostaining of control and ablated hearts. Cardiac transcription factor expression is shown at E8.5 for Gata4 (B) and Mef2c (C) and E9.5 for Islet-1 (D). The expression of genes regulating cardiomyocyte proliferation is shown at E8.5 for Yap (E), nuclear β-catenin (F), and total β-catenin (G). Sarcomeric protein expression is shown at E8.5 for α-actinin (H) and cTnT (I) and at E9.5 for Mlc2v (J). Nuclei are stained with DAPI, and cardiomyocytes are identified by cTnT (A-C, E, G) or Mlc2v (D and F). For B through J, the degree of ablation in CPC-ablated sections is 41±9% (mean±SD). ca Indicates common atrium; cv, common ventricle; and oft, outflow tract. Scale bars, 100 µm for A through G and 20 µm for H through J.
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Because the robustness of our experimental conclusions depends heavily on having an accurate assessment of the degree of ESC contribution to the hearts of chimeric embryos, we sought to exclude the possibility that Nkx2.5 Cre eGFP-DTA animals (82), presumably because of the lethality in ablated embryos with insufficient wild-type ESC contribution. Consistent with our earlier findings, embryos with up to 60% CPC loss were able to maintain normal embryonic development ( Figure 
Fractional Ablation of Embryonic Cardiomyocytes by Chimeric Complementation
Although our CPC ablation model demonstrates loss of CPCs with exquisite temporal resolution, it does not reveal whether the regenerative response to ablation requires CPCs or whether developing cardiomyocytes are capable of responding to the loss of cardiac cells during development. To address this, we performed fractional ablation of developing immature cardiomyocytes using a previously published α-myosin heavy chain-Cre (αMHC . 15 Embryos with compound αMHC
Cre/+ and ROSA26 eGFP-DTA transgenes have a wellformed heart tube at E8.0 but exhibit a hypocellular looped heart at E9.5 and the absence of a heart with pericardial edema and developmental arrest at E10.5 ( Figure 3A ). We generated several αMHC
eGFP-DTA ESC lines and selected 3 (MHC-DTA1, MHC-DTA2, and MHC-DTA3) for further study on the basis of their capacity to contribute to chimeric embryos and mice with a broad range of efficiency ( Figure 3B and 3C). Interestingly, we found that these chimeric embryos were also able to tolerate up to 50% to 60% ablation of their immature myocytes ( Figure 3D and Figure IVD and IVE in the online-only Data Supplement). Immunohistological staining for eGFP and cTnT expression showed a progressive decrease in myocardial cellularity in E9.5 chimeric embryos with >50% contribution by αMHC
eGFP-DTA ESCs ( Figure 3E ). A small number of eGFP + cardiomyocytes could be observed that may represent residual nonablated cardiomyocytes or cardiomyocytes that were dying but had not been completely eliminated. Additional immunostaining for apoptotic cells confirmed that at least a fraction of these eGFP + cardiomyocytes underwent cleavage of caspase-3 or were positive for TdT-mediated dUTP nick-end labeling ( Figure  VIA and VIB in the online-only Data Supplement). Similar to embryos that had undergone CPC ablation, there was no apparent phenotypic difference after E10.5 between surviving embryos with a high degree of ablation (ie, 50%-60%) compared with those with less fractional ablation. Taken together, these results demonstrate a robust myocardial compensatory response when cell ablation occurs during the immature cardiomyocyte stage of development.
Cell Ablation Triggers Cardiomyocyte Expansion Ex Vivo
Because the overall cardiac morphology in both ablation models was largely indistinguishable between surviving <50% to 60% ablated and control embryos, we examined whether there is a proliferative response to cell ablation by surveying the behavior of residual unablated cardiac cells ex vivo. We first dissected the heart tubes from E9.5 unablated control embryos, CPC-ablated embryos, and cardiomyocyte-ablated embryos. Next, we FACS-purified residual eGFP − cardiac cells, which are presumably responsible for recovering myocardial cellularity after ablation (Figure VIIA in the online-only Data Supplement), deposited 1 cell per well into a 96-well plate, and cultured the cells ex vivo for 7 or 14 days ( Figure 4A ). Approximately 9.5% of 5605 plated cells survived single-cell cloning.
Examination of cells within each well revealed several patterns of specification. Thirty-six percent of single-cell clones from control hearts and 20% and 44% of CPC-or cardiomyocyte-ablated clones were classified as cardiomyocytes ( Figure 4B ), exhibiting spontaneous beating and wellorganized Z lines marked by sarcomeric α-actinin expression ( Figure 4C ). Cardiomyocyte binucleation was also observed but did not significantly differ among groups (Figure VIIB in the online-only Data Supplement). A small minority of clones (2% of control, 1% of CPC-ablated, and 1% of cardiomyocyteablated clones) expressed CD31 and were highly proliferative, possessing a polygonal morphology, consistent with an endocardial/endothelial cell phenotype ( Figure 4D ). The remaining majority of clones (62% of control, 79% of CPC-ablated, and 54% cardiomyocyte-ablated clones) lacked significant sarcomeric α-actinin or CD31 expression ( Figure 4E ). These might have represented hematopoietic, epicardial, endocardial cushion mesenchyme, or neural crest-derived cells. No clones expressed smooth muscle myosin heavy chain, the definitive marker for the smooth muscle lineage.
To examine the effect of CPC or cardiomyocyte ablation on clonal cell growth potential, we counted the cardiomyocyte colony sizes resulting from single-cell plating on day 7 or 14. A normality plot indicated that the colony size distribution deviated significantly from a gaussian distribution, necessitating a ;ROSA26 eGFP-DTA transgenic embryos (right) at embryonic day (E) 8.5, E9.5, and E10.5 of development. Note that the compound transgenic embryo shows a progressive defect in cardiac morphogenesis by E9.5 and is completely missing a heart structure at E10. 5 + endocardial/endothelial cells. E, Non-CM/nonendothelial cell lacking significant sarcomeric α-actinin or CD31 expression. F, Box-and-whisker plot demonstrating median cell number and interquartile range among wells classified as containing CM colonies. Whiskers span the 10% to 90% range of values. Statistical comparisons were performed with the Kruskal-Wallis test with the Dunn correction for multiple comparisons. For G through J, control, n=4; CPC ablation, n=4, 41±9%; CM ablation, n=4, 53±12%. Immunofluorescence confocal microscopy with 1 mm z-stack imaging for proliferative CMs and endocardial cells in CPCablated (G and H) or CM-ablated (I and J) hearts at E8. 5 Figure 4F ). In contrast, no statistically significant difference was observed in cardiomyocyte number per colony between control and CPCablated embryos, although there was a trend toward greater colony size in CPC-ablated embryos at day 14 ( Figure 4F ). The lack of a significant difference in cardiomyocyte colony size between CPC-ablated and control embryos most likely resulted because CPC-ablated embryos had largely recovered their myocardial cellularity by E9.5, whereas the cardiomyocyte-ablated embryos were still actively recovering. These results indicate that cardiomyocyte ablation triggers a modest increase in cellular proliferation at E9.5 to increase cardiomyocyte number ex vivo.
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Embryonic Cardiomyocyte Proliferation Is Involved in Myocardial Regeneration After Ablation In Vivo
We next examined whether there is a proliferative response in vivo to compensate for the loss of cardiomyocytes, as suggested by our ex vivo experiments, or whether the recovery after cell ablation is due merely to a hypertrophic response in residual unablated cardiomyocytes. 30 In the case of hypertrophy, the individual cardiomyocyte size should increase without a corresponding change in myocardial cell proliferation rate, whereas in the case of proliferation, cardiomyocyte size should remain constant or decrease, accompanied by an increase in the rate of proliferation. We first performed immunostaining for proliferation markers in embryo sections from both CPC or cardiomyocyte ablation models using the mitosis marker phosphorylated histone H3 and the cell proliferation marker Ki-67 ( Figure 4G-4J) . We found that embryos from both CPC and cardiomyocyte ablation models exhibited increases in expression of both proliferation markers within their cTnT + cardiomyocytes. To see whether this correlated with changes in cardiomyocyte size, we quantified the ratio of myocardial area to the number of nuclei within cTnT + cardiomyocytes. We found, however, that the cardiomyocyte area per nucleus was not statistically different between ablated embryos and controls despite a trend toward smaller cell size ( Figure VIIIA and VIIIB in the online-only Data Supplement). This suggests that an increase in proliferation is the prevailing mechanism involved in the morphological recovery of the ablated heart.
In light of the interdependence between the myocardium and neighboring endocardium to maintain normal cardiac development, 31 we also examined whether the development of the endocardium is affected by ablation of CPCs or cardiomyocytes. At E8.5 in the CPC ablation model and at E9.5 in the cardiomyocyte ablation model, the endocardium in ablated embryos exhibited CD31 expression similar to that of controls, consistent with normal endocardial differentiation ( Figure 4G-4J ). In addition, we quantified the degree of endocardial cell proliferation in CPC-or cardiomyocyte-ablated embryos by assessing the percentage of Ki-67 + or phosphohistone H3 + endocardial cell nuclei. However, we did not observe a consistent difference in endocardial cell proliferation between ablated embryos and controls ( Figure 4G-4J) .
Because cardiomyocyte maturation is accompanied by changes in structure of the contractile unit, including greater myofibril density, more organized alignment, and an increase in sarcomere length, 32 we examined whether cardiomyocyte maturation was delayed in ablated embryos at the ultrastructural level by transmission electron microscopy ( Figure  VIIIC -VIIIE in the online-only Data Supplement). We found that at E10.5 hearts from CPC-ablated embryos exhibited a modest decrease in sarcomere thickness despite a lack of change in sarcomere length. This suggests that compensating cardiomyocytes may be phenotypically less mature because of their need for an increased rate of cell proliferation.
CPC-and Cardiomyocyte-Ablated Embryos Can Survive Into Adulthood With No Overt Cardiac Defect
The above results demonstrate that a majority of embryonic CPCs or cardiomyocytes can be ablated without triggering gross embryonic defects. To rule out more subtle congenital phenotypes in CPC-or cardiomyocyte-ablated embryos that would not manifest until late gestation or after birth, we collected chimeric live-born mice that had undergone an average of ≈40% CPC or cardiomyocyte ablation and assessed their cardiac structure by histology and their cardiac function by echocardiography at 4 to 5 weeks of age ( Figure 5A ). We found that these chimeric mice displayed the expected coat color chimerism ( Figure 5B ) with few to no residual eGFP + cells in the heart ( Figure 5C ). Compared with control unablated mice, their hearts showed similar gross overall size at the whole-organ level ( Figure 5C and 5D ) and had similar heart weights ( Figure 5E ), left ventricular chamber dimensions ( Figure 5F-5H) , and contractile function ( Figure 5I ) as measured by echocardiography. We also assessed whether a hypertrophic response occurred in ablated hearts, which could indicate whether there had been a transient history of heart failure with remodeling changes. We found, instead, no evidence of hypertrophic changes as measured by mean cardiomyocyte size in ablated versus control hearts ( Figure 5J and 5K). These findings further support our conclusion that acute CPC or cardiomyocyte loss during early embryogenesis is well tolerated in mice owing to a rapid and efficient compensatory proliferative response that supports the development of normal organ size, cardiomyocyte number, and contractile function into early adulthood.
Discussion
In this study, we developed a novel strategy to quantitatively examine the ability of a mammalian embryonic heart to compensate for rapid cell loss. Specifically, we made use of a blastocyst complementation assay that gives rise to chimeric embryos with fractional CPC or immature cardiomyocyte ablation during embryonic development. We found that embryos with up to 60% CPC loss were fully viable and could survive to adulthood. The compensatory process after CPC ablation at E7.5 was rapid and complete with little to no A, Strategy used for generation and analysis of 4-to 5-week-old mice undergoing CPC or CM ablation. B, Representative images of control and ablated chimeric adult mice. C, Bright-field and green fluorescent protein (GFP) fluorescence images of the dissected whole hearts. GFP signal is nearly absent in the hearts that have undergone ablation. D, Hematoxylin and eosin (H&E) staining of representative heart sections from control and ablated hearts. For E through K, experimental variables are represented as follows: group, number of mice examined, mean percent ablation±SD. For E through I, results are displayed with box-and-whisker plots demonstrating median value and interquartile range. Whiskers span the minimum and maximum range of values. E, Heart weight-to-body weight ratio and heart weight-to-tibia length ratio in wild-type and ablated hearts (control, n=28; CPC ablation, n=11, 39±9%; CM ablation, n=6, 42±11%). F through I, Representative M-mode echocardiography images (F) and left ventricular dimensions (G and H) and function (I) quantified by fractional shortening (FS; control, n=16; CPC ablation, n=9, 40±10%; CM ablation, n=7, 41±10%). J and K, Wheat germ agglutinin (WGA) staining of control and ablated hearts (J) and dot plot (K) displaying mean CM size. Each symbol in the dot plot represents the mean CM size in an individual heart section; a minimum of three ×32 fields per section were counted; each symbol shape represents an independent mouse; horizontal bar indicates the mean value for each group (control, n=3; CPC ablation, n=3, 51±6%; CM ablation, n=3, 51±7% 
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evidence of molecular alteration or cardiac cellular deficiency by E10.5. To examine the capacity of immature cardiomyocytes to respond to cell loss, we induced cardiomyocyte ablation at E9.0 and found, with remarkable consistency, that the loss of 50% to 60% of immature cardiomyocytes was well tolerated during embryonic development and that adult heart size and function in these animals were completely normal. Consistent with findings from newt and zebrafish cardiac regeneration, increased cardiomyocyte proliferation was evident in both CPC and cardiomyocyte ablation models. These data illustrate the significant capacity for myocardial injury repair in the embryonic mouse heart and raise the prospect that postnatal cardiac regeneration may be achievable in the mammalian heart if key mechanisms for triggering the expansion of proliferation-competent cardiomyocytes can be identified for therapeutic gain. Our study used a Cre-mediated conditional cell ablation strategy in mice to examine the response of an embryonic heart to fractional cell loss. Earlier studies have shown the remarkable ability of an adult zebrafish heart to replenish as much as a 70% to 80% loss of cardiomyocytes. 33, 34 Although the study by Drenckhahn and colleagues 12 illustrated the ability of an embryonic mammalian heart to increase cardiomyocyte proliferation in healthy cells to compensate for impaired proliferation in cardiomyocytes with metabolic derangement, the approach used was associated with an absence of apoptosis in the diseased cells and their subsequent retention. To the best of our knowledge, no study has demonstrated complete myocardial regeneration in the embryonic mouse heart after extensive and temporally controlled cell ablation. However, it should be recognized that fetal cardiomyocytes are proliferative at baseline and the ablation studies described here are likely an assessment of both the normal generative potential of fetal cardiomyocytes during cardiac development and their regenerative potential, given the increase in cardiomyocyte and cardiomyocyte precursor proliferation in the setting of cardiac cell ablation. Regardless, our data support the remarkable capacity of the fetal heart to recover from experimental cell ablation during embryonic development.
We found that the embryonic mouse heart can replace as much as 50% to 60% of developing CPCs or immature cardiomyocytes after Cre-mediated ablation and that proliferation of immature cardiomyocytes is involved in the compensatory response. In the absence of cell ablation, we observed expression by the majority of E8.5 to E9.5 cardiomyocytes of the proliferation marker Ki-67, which is detectable during the active stages of the cell cycle, including the late G1, S, G2, and M phases, but which is absent in resting cells (G0). 35 Although this finding supports that cardiomyocytes are highly proliferative during this stage of development, we found that both CPC and cardiomyocyte ablation triggered a further increase in myocyte proliferative capacity. Likewise, histone H3 phosphorylation was also found to be increased on CPC or cardiomyocyte ablation. However, its expression was observed in only a small fraction of developing myocytes, consistent with the fact that its phosphorylation is limited primarily to mitosis (M phase) 36 ( Figure 4G-4J) . As a result of the rapid differentiation of CPCs into immature cardiomyocytes at E7.5 to E8.5 of development, we were unable to document an increase in the number of Isl-1 + CPCs in the residual heart after cell ablation ( Figure 2D ). Further studies using a combination of inducible cell ablation and blastocyst complementation assays are necessary to specifically address the role of first or second heart field CPCs in the regenerative process.
Our findings also raise questions about the potential mechanisms involved in replacing the number of CPCs and cardiomyocytes after ablation. Although we believe that CPC and cardiomyocyte ablation by intracellular DTA expression should be a relatively cell-autonomous process without an exogenous inflammatory response from circulating leukocytes, differences in the amount of locally secreted signals from nonablated cardiac cells may trigger the observed proliferative response. In addition, cell-cell contact has been well described to regulate the rate of cell division. 37 The acute loss of CPCs or cardiomyocytes may result in derepression of this intrinsic negative regulator of cell proliferation. Furthermore, because the developing heart at this stage is continually receiving a new influx of cells from the second heart field, it is possible that an increase in migration and proliferation of second heart field-derived cells may be involved in myocardial regeneration in the right ventricle and outflow tract. Further work is necessary to clarify the precise mechanisms responsible for embryonic myocardial regeneration at distinct stages of development and within each heart field.
One important caveat of our findings that should be considered carefully is the potential role of other nonmyocardial cells (eg, endocardial and epicardial cells) in the compensatory process. It is well known that signaling factors released from endocardial and epicardial cells play important roles in myocardial development.
38,39 Our CPC ablation model depends on the expression of Cre from the endogenous Nkx2.5 promoter, which is known to express in pharyngeal endoderm at later stages of development, and endocardial and epicardial cells. 26 Consequently, this model may underestimate the degree of regeneration possible because it may ablate both the CPCs involved in myocardial formation and the endocardial/ epicardial cells that regulate the compensatory process.
Conclusions
We found that quantitative and fractional ablation of developing mouse CPCs and immature cardiomyocytes lead to cardiac cell loss that can be compensated for by residual unablated cells. This process is efficient and can rescue normal fetal development in hearts that have undergone up to 50% to 60% CPC or cardiomyocyte ablation. The mechanism for this compensatory response involves, in part, increased proliferation from residual immature cardiomyocytes. Identification of the mechanisms involved in responding to the loss of CPC and cardiomyocyte number by triggering their increase in proliferation may enable us to devise improved therapies for heart failure caused by myocardial cell loss. 
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CLINICAL PERSPECTIVE
A wealth of studies support the importance of developmental signaling molecules in promoting proper heart formation, from lineage commitment to cellular expansion and maturation. Disruption in these formative events during embryonic development has a profound impact on human life; congenital heart disease remains the commonest cause of birth defects worldwide. However, whether there is a requirement for a specific number of progenitor cells to fashion a normal mammalian heart and the potential mechanisms that exist to compensate for unexpected cell loss during embryonic development have not been explored. To investigate whether a mechanism is present in the developing heart to compensate for the loss of cardiac cells during the earliest stages of heart formation, we used a novel cell ablation strategy that could temporally ablate cardiac progenitor cells or immature cardiomyocytes in quantifiable fractions. By doing so, we found that, remarkably, mouse embryos could compensate for up to a 60% loss of cardiac cells without obvious morphological or functional defect. Furthermore, we show that increased proliferation of residual immature cardiomyocytes is at least partly responsible for this regenerative activity. These data provide direct evidence for the existence of a robust regenerative mechanism in the embryonic heart to compensate for cardiac progenitor cell and immature cardiomyocyte loss during development. In addition, the strategy we developed for fractional lineage-specific cell ablation should be applicable for other organ systems to address the role of progenitor cell number in development and disease and their mechanism of regeneration. ;ROSA26 LacZ whole mouse E9.5 embryos were assessed for β-Galactosidase (lacZ) activity according to previously published protocol 1 .
FACS Analysis of ESC Chimerism
For embryonic tissues, the heart, limbs, tail, head, or body were minced with a scalpel blade into 
Ex vivo single-cell clonal analysis
Heart tubes were dissected on ice at E9.5 from CD-1 control embryos, or CD-1 embryos which had been chimerized by Nkx2. Media and cultured at 37°C in 5% CO 2 in humidified air for 7 or 14 days without media changes.
TUNEL Staining
Following deparaffinization, TdT-mediated dUTP nick end labeling (TUNEL) was performed on heart sections using an ApopTag Red In Situ Apoptosis Detection Kit (Chemicon, S7165, anti- 
Electron Microscopy
E10.5 embryos were dissected in 0.1M sodium cacodylate buffer, pH 7.4 and placed into electron microscopy fixative (2.5% glutaraldehyde, 2.0% paraformaldehyde. 0.025% calcium chloride in a 0.1M sodium cacodylate buffer, pH 7.4) and allowed to fix overnight at 4ºC. The fixative was replaced with cacodylate buffer and the embryos were stored at 4ºC until further processing in a Leica Lynx automatic tissue processor. The embryos were post fixed with osmium tetroxide, en bloc stained with 2.0% uranyl acetate dehydrated in a graded ethanol series, embedded in pure epoxy resin and polymerized overnight at 60ºC. 1 μm thick sections were cut using glass knives and a Sorvall MT-1 (Dupont) ultramicrotome and floated on water droplets on glass slides. The slides were dried in a humidity chamber on a warm hot plate.
Toluidine blue stain (0.5% toluidine blue in aqueous 0.5% sodium borate) was pipetted over the However, a growing number of cCsp3 + or TUNEL + cardiomyocytes can be identified as the severity of ablation increases (middle, lower rows). ca, common atrium; cv, common ventricle.
Scale bar: 50 µm. 
